(Q44591322)

4 December 2017

title

Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women (English)

1 reference

4 December 2017

1

Olavi Ylikorkala

1 reference

4 December 2017

Bruno Cacciatore

2

1 reference

4 December 2017

Kaija Halonen

3

1 reference

4 December 2017

Riitta Lassila

4

1 reference

4 December 2017

Risto Lammintausta

5

1 reference

4 December 2017

Eeva-Marja Rutanen

6

1 reference

4 December 2017

Jorma Heikkinen

7

1 reference

4 December 2017

Janne Komi

8

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

full work available at URL

4 December 2017

https://journals.lww.com/10.1097/01.GME.0000063566.84134.98

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

12 March 2024

1 reference

4 December 2017

volume

10

1 reference

4 December 2017

issue

5

1 reference

4 December 2017

page(s)

440-447

1 reference

Postmenopausal hormone therapy for prevention of fractures: how good is the evidence?

4 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Perspective. How many women have osteoporosis?

12 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials

12 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

12 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Hormone therapy to prevent disease and prolong life in postmenopausal women

12 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

12 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator

12 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats

12 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial

12 March 2024

10

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.

12 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

The protective effects of estrogen on the cardiovascular system

12 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease

12 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

12 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study

12 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Influence of fibrinogen on cardiovascular disease

12 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women

12 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Baseline diene conjugation in LDL lipids: an indicator of circulating oxidized LDL.

12 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

The calcium-dependent nitric oxide production of human vascular endothelial cells in preeclampsia

12 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels.

12 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Thromboxane dominance and prostacyclin deficiency in habitual abortion

12 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Homocysteine and atherothrombosis

12 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.

12 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

12 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Induction of calcium-dependent nitric oxide synthases by sex hormones.

12 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells

12 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors

12 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women

12 March 2024

33

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Stable over-expression of estrogen receptor-alpha in ECV304 cells inhibits proliferation and levels of secreted endothelin-1 and vascular endothelial growth factor

12 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane

12 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Hormone replacement therapy modifies the capacity of plasma and serum to regulate prostacyclin and endothelin-1 production in human vascular endothelial cells

12 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Evidence for a rapid inhibitor to tissue plasminogen activator in plasma

12 March 2024

38

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study. The PLAT Group.

12 March 2024

39

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction

12 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects.

12 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

12 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

12 March 2024

43

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

12 March 2024

44

1 reference

https://api.crossref.org/works/10.1097/01.GME.0000063566.84134.98

12 March 2024

Identifiers

1 reference

4 December 2017

1 reference